Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11628019 | 0.86 | KCNA5 (0.47) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL3574840 | 0.85 | KCNA5 (0.45) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL22060303 | 0.84 | CYP19A1 (0.47) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL28632031 | 0.81 | KCNA5 (0.50) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL18193367 | 0.81 | KCNA5 (0.50) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL14698924 | 0.80 | KCNA5 (0.49) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL14962064 | 0.79 | CYP19A1 (0.40) | CYP3A4CYP19A1CYP3A5 | |
| SCHEMBL9494010 | 0.78 | KCNA5 (0.49) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL12238648 | 0.78 | CYP3A4 (0.49) | KCNA5CYP3A4CYP1A2LMNACYP11B1 | |
| SCHEMBL11631301 | 0.78 | KCNA5 (0.43) | KCNA5CYP3A4CYP1A2LMNACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2021-06-24 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10906877-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC | 2021-02-02 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| EP-3572405-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Knopp Biosciences LLC (US) | 2019-11-27 | — | — | EP | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3191457-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2018-05-31 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | KCNA5 28/4885CYP3A4 2565/4885CYP1A2 2822/4885 |
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | KCNA5 28/4885CYP3A4 2565/4885CYP1A2 2822/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | KCNA5 28/4885CYP3A4 2565/4885CYP1A2 2822/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
| US-10906877-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | KCNA5 28/4885CYP3A4 2565/4885CYP1A2 2822/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | KCNA5 28/4885CYP3A4 2565/4885CYP1A2 2822/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KCNA5 27/4885CYP3A4 1656/4885CYP1A2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.